Onkológia 6/2019
Comparative studies of reference biological drugs and related biological drugs
Biosimilars enable economic competition, alleviate the financial burden for insurances, and may to reduce the finance spent on treatment. Biosimilars are not completely identical to the original drug. The approval of biosimilars is only partially based on results of randomized clinical studies. Based on the current clinical data and experiences, biosimilars in oncology show no significant differences in pharmacokinetics, efficacy, and safety in comparison to the patented originals.
Keywords: biosimilars, biological drugs, oncology












